Evidence map›Paper›PMID 18453363›Full record

ReviewProceedings of the American Thoracic Society2008

Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Jeremy A Falk, Omar A Minai, Zab Mosenifar

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Proceedings of the American Thoracic Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04520230 (Comparative Study Between Three Therapeutic Options for Treatment of Chronic Obstructive Pulmonary Disease Patients), which is not on this map. Cited by 44 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 5 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04520230 phase4completednot on this mapstarted 2014, after this paper: background citation

Comparative Study Between Three Therapeutic Options for Treatment of Chronic Obstructive Pulmonary Disease Patients

TypeinterventionalSponsorTanta UniversityRan2014 to 2019Enrolled45ConditionsCOPDArmsBudesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid, Tiotropium 18 mcg capsule inhaled once daily + Budesonide, Formoterol/Tiotropium
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 5 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Inhaled corticosteroids andBMJ open respiratory research · 2024
    Observational
  16. Article
  17. Observational
  18. Article
  19. Glucocorticoid Use in Patients Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.International journal of chronic obstructive pulmonary disease · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jeremy A FalkDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center for the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA. falkja@cshs.org
Omar A Minai
Zab Mosenifar
Cedars-Sinai Medical Center · USCleveland Clinic · US

Funding

CLINICAL COORDINATING CENTER FOR LVRS-N01HR76119-268076119-268076119N01HR076119 · HR · JOHNS HOPKINS UNIVERSITY · PI PIANTADOSI, STEVEN · 1997 to 2006
$871k
LUNG VOLUME REDUCTION SURGERY--CLINICAL CENTERN01HR076118 · HR · UNIVERSITY OF WASHINGTON · PI ALBERT, RICHARD K · 1997 to 2000
$225k
LUNG VOLUME REDUCTION SURGERY--CLINICAL CENTERN01HR076113 · HR · UNIVERSITY OF PENNSYLVANIA · PI KAISER, LARRY · 1997 to 2000
$208k
CLNICAL CENTER FOR LVRSN01HR076104 · HR · CEDARS-SINAI MEDICAL CENTER · PI MCKENNA, RICHARD · 1997 to 2000
$153k
CLNICAL CENTER FOR THE LVRSN01HR076102 · HR · BRIGHAM AND WOMEN'S HOSPITAL · PI REILLY, JOHN J · 1997 to 2000
$150k
CLINICAL CENTER FOR LVRSN01HR076114 · HR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KEENAN, ROBERT J · 1997 to 2000
$147k
LUNG VOLUME REDUCTION SURGERY--CLINICAL CENTERN01HR076110 · HR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FERNANDO, MARTINEZ J · 1997 to 2000
$146k
LUNG VOLUME REDUCTION SURGERY--CLINICAL CENTERN01HR076111 · HR · NATIONAL JEWISH HEALTH · PI CHERNIACK, REUBEN M · 1997 to 2000
$144k
CLINICAL CENTER FOR THE LUNG VOLUME REDUCTION SURGERYN01HR076106 · HR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBURG, MARK E · 1997 to 2000
$143k
CLINICAL CENTER FOR THE LUNG VOLUME REDUCTION SURGERYN01HR076103 · HR · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RIES, ANDREW L · 1997 to 2000
$142k
CLNICAL CENTER FOR LVRSN01HR076105 · HR · CLEVELAND CLINIC FOUNDATION · PI MAURER, JANET R. · 1997 to 2000
$137k
CLINICAL CENTER FOR THE LUNG VOLUME REDUCTION SURGERYN01HR076101 · HR · BAYLOR COLLEGE OF MEDICINE · PI ESPADA, RAFAEL · 1997 to 2000
$134k
NHLBI NIH HHS N01HR76101NHLBI NIH HHS N01HR76102NHLBI NIH HHS N01HR76103NHLBI NIH HHS N01HR76104NHLBI NIH HHS N01HR76105NHLBI NIH HHS N01HR76106NHLBI NIH HHS N01HR76107NHLBI NIH HHS N01HR76108NHLBI NIH HHS N01HR76109NHLBI NIH HHS N01HR76110NHLBI NIH HHS N01HR76111NHLBI NIH HHS N01HR76112NHLBI NIH HHS N01HR76113NHLBI NIH HHS N01HR76114NHLBI NIH HHS N01HR76115NHLBI NIH HHS N01HR76116NHLBI NIH HHS N01HR76118NHLBI NIH HHS N01HR76119
6 · The paper itself

Abstract

Systemic and local inflammation is central to the pathophysiology of chronic obstructive pulmonary disease (COPD). Increased levels of inflammation have been linked to a more progressive course in COPD and have been shown to be present during an exacerbation. Decreases in inflammatory cytokines, C-reactive protein, and inflammatory cells have been observed with corticosteroid use, suggesting a possible mechanism for a therapeutic benefit of steroids. No available data support the routine use of systemic corticosteroids in stable COPD; however, short courses during exacerbations are likely to improve length of hospitalization, lung function, and relapse rate. Inhaled corticosteroids (ICS) decrease the rate of exacerbation and may improve the response to bronchodilators and decrease dyspnea in stable COPD. No study shows that ICS reduce the loss of lung function; however, recent data suggest a possible survival benefit when combined with long-acting beta agonists. There are limited data on the use of ICS in the treatment of acute exacerbations of COPD, and its role in this setting must be more clearly defined. The empiric use of systemic corticosteroids perioperatively represents another area of uncertainty. The role of pharmacogenetics in the metabolism of corticosteroids in COPD is evolving but may be partially responsible for the observed variability in patient responsiveness. The potential benefits of systemic or inhaled corticosteroid use must be weighed against the risk of known toxicities.

Indexed as

Administration, InhalationAdministration, OralAdrenal Cortex HormonesClinical Trials as TopicHumansInflammationNebulizers and VaporizersPulmonary Disease, Chronic ObstructiveQuality of LifeAdrenal Cortex Hormones

Identifiers

PMID18453363
PMCPMC2645327
OpenAlexW1989631589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.